Curanium drugs, used as muscle relaxants, primarily function by acting competitively on acetylcholine (Ach) receptors. This action occurs at the neuromuscular junction, specifically targeting post-synaptic receptors. When these drugs bind to the Ach receptors, they prevent acetylcholine, a neurotransmitter, from attaching to its site. This competitive inhibition blocks neuromuscular transmission, ultimately leading to muscle relaxation. By obstructing acetylcholine's action, Curanium drugs effectively reduce muscle contractions and are utilized in various medical procedures requiring muscle relaxation. Understanding this mechanism highlights their role in competitive inhibition at the receptor level.